<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12944">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00440505</url>
  </required_header>
  <id_info>
    <org_study_id>AAAA4808</org_study_id>
    <nct_id>NCT00440505</nct_id>
  </id_info>
  <brief_title>Effect of Nicotine on Chronic Pelvic Pain</brief_title>
  <official_title>Effect of Nicotine on Chronic Pelvic Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether transdermal nicotine reduces pain among women
      with chronic pelvic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential subjects are female non-smokers presenting to their physicians for treatment of
      chronic pelvic pain. When consented, the subjects fill out a questionnaire on demographic
      information and pain experience. The trial is conducted at home over three days. Each
      subject uses three different levels of nicotine (0mg, 5mg, and 10mg) administered in a
      random order; the study is double-blinded and patients act as their own controls. Subjects
      apply the placebo or nicotine patches in the morning and remove them in the evening when
      they fill out a pain diary for the day. During the study, patients will continue their
      typical course of pain medication and report pain medication use in the pain diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain Score</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Pain assessment by patient reported in visual analog score (VAS) with 0=no pain and 10=worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Self-assessment of Psychological Distress</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient self-assessment of psychological distress in brief rating scale with no psychological distress=0 and maximum psychological distress=90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported an Increase in Daily Pain Medication Regime</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants who reported increases in daily pain medication after treatment with each intervention compared to their normal daily pain medication regime.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea assessment by patient reported on a numerical rating scale (NRS) with 0=no nausea and 10=extreme nausea.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine (5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine (10 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine (5 mg)</intervention_name>
    <description>Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.</description>
    <arm_group_label>Nicotine (5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine (10 mg)</intervention_name>
    <description>Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.</description>
    <arm_group_label>Nicotine (10 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic pelvic pain

          -  Aged 18-60 years

          -  Female

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Cardiovascular disease

          -  Current analgesic abuse

          -  Pregnancy

          -  Current usage of nicotine patch or gum

          -  Allergy to adhesive tape
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela Flood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessamyn Conell-Price, BA</last_name>
    <role>Study Director</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <lastchanged_date>January 12, 2011</lastchanged_date>
  <firstreceived_date>February 26, 2007</firstreceived_date>
  <firstreceived_results_date>October 1, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Pamela Flood</name_title>
    <organization>Columbia University</organization>
  </responsible_party>
  <keyword>chronic pain</keyword>
  <keyword>pelvic pain</keyword>
  <keyword>nicotine patch</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pelvic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This double-blind prospective study was approved by the Institutional Review Board of Columbia University Medical Center. Written consent was obtained from all subjects. Women presenting with chronic pelvic pain to a gynecologist or to the pain clinic at New York Presbyterian Hospital were eligible for inclusion.</recruitment_details>
      <pre_assignment_details>Twenty-six women were recruited for the study. Six women declined to participate after consenting but before commencing treatment; these women are not included in the analysis.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo First, Then Nicotine 5 mg, Then Nicotine 10 mg</title>
          <description>Placebo patch for one day in first intervention period, nicotine 5 mg patch for one day in second intervention period and nicotine 10 mg patch for one day in the third intervention period.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Nicotine 10 mg, Then Nicotine 5 mg</title>
          <description>Placebo patch for one day in first intervention period, nicotine 10 mg patch for one day in second intervention period and nicotine 5 mg patch for one day in the third intervention period.</description>
        </group>
        <group group_id="P3">
          <title>Nicotine 5 mg First, Then Nicotine 10 mg, Then Placebo</title>
          <description>Nicotine 5 mg patch for one day in first intervention period, nicotine 10 mg patch for one day in second intervention period and placebo patch for one day in the third intervention period.</description>
        </group>
        <group group_id="P4">
          <title>Nicotine 5 mg First, Then Placebo, Then Nicotine 10 mg</title>
          <description>Nicotine 5 mg patch for one day in first intervention period, placebo patch for one day in second intervention period and nicotine 10 mg patch for one day in the third intervention period.</description>
        </group>
        <group group_id="P5">
          <title>Nicotine 10 mg First, Then Nicotine 5 mg, Then Placebo</title>
          <description>Nicotine 10 mg patch for one day in first intervention period, nicotine 5 mg patch for one day in second intervention period and placebo patch for one day in the third intervention period.</description>
        </group>
        <group group_id="P6">
          <title>Nicotine 10 mg First, Then Placebo, Then Nicotine 5 mg</title>
          <description>Nicotine 10 mg patch for one day in first intervention period, placebo patch for one day in second intervention period and nicotine 5 mg patch for one day in the third intervention period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score</title>
        <description>Pain assessment by patient reported in visual analog score (VAS) with 0=no pain and 10=worst pain.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>This analysis was per protocol. One patient dropped out of the study before the third intervention period. This patient does not have data for the 10 mg nicotine patch.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine 5 mg</title>
            <description>Nicotine 5 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine 10 mg</title>
            <description>Nicotine 10 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pain Score</title>
            <description>Pain assessment by patient reported in visual analog score (VAS) with 0=no pain and 10=worst pain.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7.1" spread="3.1"/>
                  <measurement group_id="O2" value="6.4" spread="3.0"/>
                  <measurement group_id="O3" value="6.9" spread="3.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Self-assessment of Psychological Distress</title>
        <description>Patient self-assessment of psychological distress in brief rating scale with no psychological distress=0 and maximum psychological distress=90.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis was per protocol. One patient dropped out of the study before the third intervention period. This patient does not have data for the 10 mg nicotine patch.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine 5 mg</title>
            <description>Nicotine 5 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine 10 mg</title>
            <description>Nicotine 10 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                  <measurement group_id="O3" value="19"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Self-assessment of Psychological Distress</title>
            <description>Patient self-assessment of psychological distress in brief rating scale with no psychological distress=0 and maximum psychological distress=90.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="40.2" spread="18.3"/>
                  <measurement group_id="O2" value="36.7" spread="18.6"/>
                  <measurement group_id="O3" value="37.5" spread="18.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported an Increase in Daily Pain Medication Regime</title>
        <description>Number of participants who reported increases in daily pain medication after treatment with each intervention compared to their normal daily pain medication regime.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis was per protocol. Only data from those patients who returned the pain diaries with the above information to the research staff by mail were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine 5 mg</title>
            <description>Nicotine 5 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine 10 mg</title>
            <description>Nicotine 10 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants Who Reported an Increase in Daily Pain Medication Regime</title>
            <description>Number of participants who reported increases in daily pain medication after treatment with each intervention compared to their normal daily pain medication regime.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="3"/>
                  <measurement group_id="O3" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea</title>
        <description>Nausea assessment by patient reported on a numerical rating scale (NRS) with 0=no nausea and 10=extreme nausea.</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>This analysis was per protocol. Only data from those patients who returned the pain diaries with the above information to the research staff by mail were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O2">
            <title>Nicotine 5 mg</title>
            <description>Nicotine 5 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
          <group group_id="O3">
            <title>Nicotine 10 mg</title>
            <description>Nicotine 10 mg patch administered for one day in either first intervention period, second intervention period or third intervention period.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="13"/>
                  <measurement group_id="O3" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Nausea</title>
            <description>Nausea assessment by patient reported on a numerical rating scale (NRS) with 0=no nausea and 10=extreme nausea.</description>
            <units>Units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.3" spread="1.8"/>
                  <measurement group_id="O2" value="2.3" spread="2.1"/>
                  <measurement group_id="O3" value="2.3" spread="2.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Non-smokers with the placebo patch</description>
        </group>
        <group group_id="E2">
          <title>Nicotine 5mg</title>
          <description>Non-smokers with the Nicotine 5mg patch</description>
        </group>
        <group group_id="E3">
          <title>Nicotine 10mg</title>
          <description>Non-smokers with the Nicotine 10mg patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pamela Flood, MD</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-2008</phone>
      <email>pdf3@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
